The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis

摘要: Background The combination of chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) currently has become the hotspot issue in treatment non-small lung cancer (NSCLC). This systematic review was conducted to compare efficacy safety synchronous these two treatments with EGFR TKIs or alone advanced NSCLC. Methods EMBASE, PubMed, Central Registry Controlled Trials Cochrane Library (CENTRAL), Chinese biomedical literature database (CNKI) meeting summaries were searched. Phase II/III randomized controlled trials selected by which patients NSCLC receive a mode vs. alone. Results A total six (RCTs) including 4675 enrolled review. meta-analysis demonstrated that group did not reach satisfactory results; there no significant difference overall survival (OS), time progression (TTP) objective response rate (ORR), compared monotherapy (OS: HR = 1.05, 95%CI 0.98–1.12; TTP: 0.94, 0.89–1.00; ORR: RR 1.07, 0.98–1.17), OS progression-free (PFS), 1.10, 95% CI 0.83–1.46; PFS: 0.86, 0.67–1.10). who received combined therapy presented increased incidences grade 3/4 anemia (RR 1.40, 1.10–1.79) rash 7.43, 4.56–12.09), chemotherapy, 6.71, 1.25–35.93) fatigue 9.60, 2.28–40.86) TKI monotherapy. Conclusions is superior for first-line